Last reviewed · How we verify
PrevenarTM
Prevenar is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against Streptococcus pneumoniae serotypes.
Prevenar is a pneumococcal conjugate vaccine that stimulates the immune system to produce antibodies against Streptococcus pneumoniae serotypes. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of invasive pneumococcal disease in adults ≥50 years of age.
At a glance
| Generic name | PrevenarTM |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Pneumococcal conjugate vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (serotype-specific) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Prevenar conjugates capsular polysaccharides from multiple serotypes of S. pneumoniae to a protein carrier (CRM197), enhancing immunogenicity and T-cell dependent responses. This allows the vaccine to induce protective antibodies in both children and adults, preventing invasive pneumococcal disease including bacteremia, meningitis, and pneumonia caused by vaccine-covered serotypes.
Approved indications
- Prevention of invasive pneumococcal disease in infants and children
- Prevention of invasive pneumococcal disease in adults ≥50 years of age
Common side effects
- Injection site erythema
- Injection site swelling
- Injection site pain
- Fever
- Irritability/fussiness
- Drowsiness
Key clinical trials
- Co-administration of Pneumococcal Conjugate Vaccine With DTPa-IPV-Hib Versus Co-administration With DTPa-HBV-IPV/Hib (PHASE3)
- Persistence of Antibodies at 3, 4 and 6 Years of Age After Vaccination With Meningococcal, Pneumococcal and Hib Vaccines (PHASE3)
- Study Evaluating 7-Valent Pneumococcal Conjugate Vaccine in Healthy Infants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PrevenarTM CI brief — competitive landscape report
- PrevenarTM updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI